For the Inventor, By the Inventor

Enter assignee name

Dublin, Ireland

Amarin Pharmaceuticals Ireland Limited

USPTO Granted Patents = 141

CIPO Patents = 2

EPO Patents = 18

Trademarks = 15

Forward Citations = 4,533

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Paresh Soni (120 out of 123 patents)

Mehar Manku (88 out of 107 patents)

Pierre Wicker (87 out of 88 patents)

4. Rene Braeckman (87 out of 88 patents)

5. Ian Osterloh (86 out of 89 patents)

6. Joseph S Zakrzewski (16 out of 17 patents)

7. Jonathan Rowe (5 out of 8 patents)

8. Richard Preston Mason (4 out of 4 patents)

9. Sephy Philip (2 out of 2 patents)

10. William Stirtan (1 out of 1 patent)

11. Anthony Clarke (1 out of 7 patents)

12. Rene Breackman (1 out of 1 patent)

13. George Grandolfi (1 out of 1 patent)

14. Mehar Manku (0 patent)

15. Ian Osterloh (0 patent)

Core Competencies:

Cardiovascular Events

Atrial Fibrillation

Triglycerides

Heart Failure

Mixed Dyslipidemia

Eicosapentaenoic Acid

Statin Therapy

Nonalcoholic Steatohepatitis

Apolipoprotein C-III

High-Sensitivity C-Reactive Protein

Omega-3 Fatty Acids

Cardiovascular Disease

141 patents: Sort by Forward Citations

1. 12427134 - Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter (2025-09-30),

2. 12246003 - Methods of reducing the risk of cardiovascular events in a subject (2025-03-11),

3. 12171738 - Compositions and methods for lowering triglycerides (2024-12-24),

4. 11986452 - Methods of reducing the risk of heart failure (2024-05-21),

5. 11717504 - Methods of reducing the risk of cardiovascular events in a subject (2023-08-08),

6. 11712429 - Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity (2023-08-01),

7. 11712428 - Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity (2023-08-01),

8. 11690820 - Methods of treating mixed dyslipidemia (2023-07-04),

9. 11547710 - Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin (2023-01-10),

10. 11464757 - Compositions and methods for lowering triglycerides (2022-10-11),

11. 11446269 - Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids (2022-09-20),

12. 11439618 - Compositions and methods for lowering triglycerides (2022-09-13),

13. 11400069 - Methods of treating mixed dyslipidemia (2022-08-02),

14. 11369582 - Methods of reducing the risk of cardiovascular events in a subject (2022-06-28),

15. 11298333 - Methods of reducing the risk of cardiovascular events in a subject (2022-04-12),

Amarin Pharmaceuticals Ireland Limited is a biopharmaceutical company that is focused on the development and commercialization of therapeutics for the treatment of cardiovascular diseases. Their flagship product, Vascepa, is an FDA-approved prescription medicine for reducing cardiovascular risk in certain patients. Amarin Pharmaceuticals Ireland Limited is committed to improving patient outcomes and transforming the lives of individuals affected by cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

141 Patents

#14 in Dublin

#19 in Ireland

#5,609 in the World

Dublin, Ireland

Amarin Pharmaceuticals Ireland Limited

Forward Citations = 4,533

13 inventors:

Paresh Soni (120 out of 123 patents)

Mehar Manku (88 out of 107 patents)

Pierre Wicker (87 out of 88 patents)

4. Rene Braeckman (87 out of 88 patents)

5. Ian Osterloh (86 out of 89 patents)

Please report any incorrect information to support@idiyas.com

Loading…